Bio-Rad Laboratories, Inc. announced a partnership with Seegene, Inc., for the clinical development and commercialization of infectious disease molecular diagnostic products. Under the terms of the agreement, Seegene, based in Seoul, Korea, will provide diagnostic tests for use on Bio-Rad's CFX96™ Dx Real-Time PCR System for U.S. markets pending clinical development and clearance from The U.S. Food & Drug Administration (FDA). Seegene assays offer multiplex real-time PCR detection and differentiation, with high sensitivity and specificity of up to seven targets in a single reaction.

The assays deliver results in approximately four hours.